Here are three takeaways:
1. Mazor and its partner, Medtronic, will team up to commercialize, co-promote and market the platform.
2. Medtronic made a $40 million third trance investment in the robotics company this year.
3. During the second quarter, Mazor received 16 Mazor X purchase orders in the U.S. The company anticipates the CE mark will increase purchases in Europe.
More articles on devices:
16 new spine, orthopedic device launches & releases — Sept. 27, 2017
OrthAlign raises $10M in financing for research & development expansion: 5 insights
Onkos Surgical launches Precision Oncology Platform: 5 key points
